Handelsavisen
prelaunch
Companies ›Information Technology ›300253.SZ
30
300253.SZ — Shenzhen Stock Exchange IT Services & Consulting

Winning Health Technology Group Co Ltd

¥6,95
Open in Charts → Attach watcher ⌖
— —
CNY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
0,00 %
Op margin
-19,9 %
ROE
-6,7 %
Net margin
-17,8 %
Debt / equity
0,26
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Winning Health Technology Group Co Ltd provides IT services, primarily in the health care technology sector.

Business. Winning Health Technology Group Co Ltd (300253.SZ) is a technology company operating in the IT Services & Consulting industry. The firm provides IT services, though specific details regarding its operating segments and geographic mix are not available. The company is listed on the Shenzhen Stock Exchange under the ticker 300253.SZ. Headquarters location information is not provided in the available data.

Classification92 %
SectorTechnology
Business sectorSoftware & IT Services
IndustryIT Services & Consulting
ActivityIT Services
Generated · model-assisted
Sell-side consensus
BUY3 analysts
3 buy0 hold0 sell
Avg 12m price target12,41

Analyst recommendations

3 analysts · consensus Buy
Buy3
Hold0
Sell0
12-month price target
12,41
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score→
33
composite score
Valuation
—
valuation pending
Analysts→
Buy
3 analysts · indicative
Ownership
—
not yet wired
Profitability→
-6,7 %
return on equity
Quality→
59
quality score (0-100)

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 300253.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,2 %+1,6 %+2,4 %
    Energy+1,2 %+5,3 %+1,4 %
    Real Estate+0,7 %+4,1 %+0,8 %
    Health Care+0,7 %−0,5 %+0,8 %
    Consumer Discretionary+0,3 %+8,7 %+0,5 %
    Information Technology · THIS SECTOR−0,3 %+6,6 %−0,1 %
    Financials−0,3 %−4,5 %−0,1 %
    Consumer Staples−1,0 %+3,0 %−0,8 %
    Utilities−1,5 %−21,2 %−1,3 %
    Industrials−1,7 %−2,3 %−1,6 %
    Communication Services———

    Developing storylines

    No tracked sagas currently linked to 300253.SZ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-07-07 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-07-08 · AU
    • Rate decisionBank of Canada rate decision (press conf.)2026-07-15 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-07-16 · EU
    • Rate decisionBank of Japan rate decision (press conf.)2026-07-16 · JP
    • Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Composite score33 / 100
    Composite score 0-100 · Data quality 0,59
    Data quality0,59 / 1.00

    Synthesis

    Business

    Winning Health Technology Group Co Ltd (300253.SZ) is a technology company operating in the IT Services & Consulting industry. The firm provides IT services, though specific details regarding its operating segments and geographic mix are not available. The company is listed on the Shenzhen Stock Exchange under the ticker 300253.SZ. Headquarters location information is not provided in the available data.

    Classification92 %
    SectorTechnology
    Business sectorSoftware & IT Services
    IndustryIT Services & Consulting
    ActivityIT Services
    AI synthesis
    GENERATED

    Winning Health Technology Group Co Ltd has a debt-to-equity ratio of 0.26, indicating a relatively conservative capital structure with limited leverage. The company’s liquidity position is characterized by a current ratio of 2.83, suggesting it can cover short-term obligations with a buffer. However, the company’s free cash flow is negative at -424.99 million CNY, and capital expenditures are -220.35 million CNY, signaling ongoing investment in operations despite cash outflows.

    Profitability metrics are weak, with a return on equity of -6.69% and a return on assets of -4.39%, both significantly below the industry median for IT services. The company reported a net loss of 373.88 million CNY and an operating loss of 418.42 million CNY, indicating operational inefficiencies or declining margins. Gross profit of 691.43 million CNY represents 32.8% of revenue, which is below the industry average for health care technology firms.

    The company’s revenue of 2.11 billion CNY is concentrated in a single business segment, with no disclosed geographic diversification in the latest financials. This lack of diversification increases exposure to sector-specific risks, particularly in the health care IT space.

    Looking ahead, the company is expected to face continued pressure on profitability, with no clear path to positive net income in the near term. Analysts have assigned a mean price target of 12.41 CNY, with a median of 13.05 CNY, but the company’s current financial performance does not support a strong upward trajectory.

    The risk assessment highlights liquidity as a medium concern, with negative net cash after subtracting total debt. While dilution risk is currently low, the company’s negative free cash flow and ongoing capital expenditures could necessitate future equity or debt financing, which may increase dilution pressure.

    Recent filings and transcripts have not disclosed any material events that would significantly alter the company’s financial outlook. Analysts have issued a mixed set of recommendations, with two strong-buy ratings and one buy rating, but no hold or sell ratings.

    Key takeaways
    • The company has a weak profitability profile, with negative returns on equity and assets.
    • Liquidity is moderate, but free cash flow is negative, signaling ongoing cash outflows.
    • Revenue is concentrated in a single business segment, increasing exposure to sector-specific risks.
    • Analysts are cautiously optimistic, but the company’s financial performance does not support a strong upward trajectory.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥6,95
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    ¥5.59B
    Net cashⓘ
    -¥1.46B
    Current ratioⓘ
    2.8
    Debt / equityⓘ
    0.3
    ROAⓘ
    -4.4%
    ROEⓘ
    -6.7%
    Cash conversionⓘ
    -149.0%
    CapEx / revenueⓘ
    -10.5%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,07
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    3
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-05-21 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate0,02
    Revenue—no estimate—no estimate2,5B CNY
    Operating income—no estimate—no estimate—no estimate
    Full-year consensus mean (period as reported by source) · consensus in CNY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-07-07

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution2 analysts
    Strong buy1
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target¥12,41 · Median ¥13,05
    Low ¥11,14High ¥13,05
    EPS surprise
    −946,0 %
    reported vs consensus · miss
    Revenue surprise
    −14,1 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low¥11,14
    Mean¥12,41
    Median¥13,05
    High¥13,05
    Spot¥6,95
    +78.6 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-19,9 %Bottom quartile
    Net Margin-17,8 %Bottom quartile
    ROE-6,7 %Bottom quartile
    Capex / Rev-10,5 %Bottom quartile
    D/E0,26Below median
    Cash Conv-1,49Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Winning Health Technology Group Co Ltd Market data — financials · 2026-05-26
    • Winning Health Technology Group Co Ltd Market data — analyst estimates · 2026-05-26
    • Winning Health Technology Group Co Ltd Market data — ESG · 2026-05-26

    Ownership & reference

    Leadership

    • Jiaming SunSenior Vice President
    • Tao WangPresident, Director

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    300253.SZCanonical
    Shenzhen Stock Exchange · CNY

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-07-07 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage